1. Volume 56, Pages S28-S30 (July 1999)
Role of circulating lipid abnormalities in chronic renal allograft rejection 
Bertram L. Kasiske, M.D 
Kidney International 
Volume 56, Pages S28-S30 (July 1999)
DOI: /j x
Copyright © 1999 International Society of Nephrology Terms and Conditions

2. Figure 1
Potential role of antilipemic therapy in chronic allograft rejection. 3-Hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors may decrease low density lipoprotein cholesterol levels, which, in turn, could theoretically increase free cyclosporine A (CsA) levels. CsA could reduce intimal damage by inhibiting T lymphocytes. Antioxidants could reduce the formation of oxidized low-density lipoprotein and thereby reduce foam cell formation. Abbreviations are: LDL, low-density lipoprotein; MP, macrophage.
Kidney International  , S28-S30DOI: ( /j x)
Copyright © 1999 International Society of Nephrology Terms and Conditions